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residual disease in patients with advanced
ovarian cancer following upfront radical
debulking surgeryWehave readwith great interest the article byHeitz et al. (2016), and
would congratulate with them for the effort in investigating technical
reasons of suboptimal debulking in advanced epithelial ovarian cancer
(AEOC). In this study, the Authors suggest that, because of amuch longer
median overall survival (OS) in complete/optimally resected patients,
pre-operative identiﬁcation of unresectable sites may help to develop
adequate surgical training and to identify patients thatwould better ben-
eﬁt from alternative strategies. Their overall rate of patients unsuitable
for primary debulking surgery (PDS) is 30.3%, including women primar-
ily excluded from surgery and those not achieving RT ≤ 1 cm.
In the Discussion section, the Authors compare their rates of optimal
debulking with those from other experiences (Gallotta et al., 2013; Chi
et al., 2009; Aletti et al., 2009), questioning the role of staging-laparos-
copy (S-LPS) according to Rome's experience. They refer to the paper
published in 2013 (Gallotta et al., 2013), where 50.7% of patients were
deemed not eligible for PDS, thus being triaged directly to neoadjuvant
chemotherapy (NACT). Moreover, they extrapolate the data to the en-
tire Rome's population, showing a ﬁnal rate of complete and optimal
debulking of 30% and 13.7%, respectively. They conclude “this strategy
seems to lead to a selection and separation of patients in different cohorts
but without substantially improving outcome”.
In the light of these statements, some clariﬁcations are needed.
1. As acknowledged by the Authors, the ﬁrst limitation of their study
lies in the comparison with data published earlier, since inclusion
criteria, treatments and follow-up might be different. In particular,
the ﬁrst series investigating S-LPS refer to the period 2006–2010,
when upper abdominal techniques were recently introduced in our
practice (Gallotta et al., 2013). This is proven by themost recent pub-
lication by Petrillo et al. (2015), who reported a complete/optimal re-
section rates of 57.7% and 23.1% respectively, which appear in line
with the ESGO recommendations (Advanced (Stage III-IV) Ovarian
Cancer Surgery Quality Indicators), and consistent with those
shown by the German group (66.1% p-value = 0.114; 25.4%; p-
value = 0.308). The minor differences in terms of absent RT, still
existing between Petrillo and Heitz's series, besides a general accept-
ed variability, may be explained with the inclusion of FIGO stage IIIB
patients in German “PDS group” (13.0%) and the exclusion of high-
risk cases (data not shown in the German paper). The rate of subop-
timal resection in the Rome's series was 19.2% (n=45/234 patients)
with respect to 8.5% (n= 49/578 patients) reported in the German's
experience (p-value = 0.001). However, among the 45 Roman
women with RT N 1 cm, 18 of 234 (7.7%) were deemed unresectableDOIs of original article: http://dx.doi.org/10.1016/j.ygyno.2016.03.015,
http://dx.doi.org/10.1016/j.gore.2016.11.004.
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matosis and/or PIV ≥ 10, thus being pre-operatively excluded from
PDS according to the German deﬁnition. Therefore, only an accept-
able number of cases (27/234, 11.5%) received unnecessary laparot-
omy, thus overlapping with the German experience (p-value =
0.219).
Furthermore, we clearly and frequently stated that in our Institution
the poorest ECOG-PS and/or ASA score and/or pre-operative imaging
predicting sub-optimal cytoreduction are not considered a priori
criteria to abort surgery. Indeed, the rate of ECOG-PS ≥ 2we reported
(ranging from 19.7% to 9.4%) further supports the absence of any pa-
tients' selection. In otherwords, all cases admitted at ourDepartment
are assessed for PDS, and represent our entire denominator. The ﬁnal
number of unresectable/suboptimally resected cases can be easily
identiﬁed among the entire amount of S-LPS performed, and has de-
creased over the time reaching the value of 9.7% (Vizzielli et al.,
2016).
2. To deﬁnitively solve the issue whether S-LPS is able to separate pa-
tients in different cohorts without substantially affecting the out-
come but sparing unnecessary morbidity/mortality, we designed a
randomized clinical trial in which AEOC women were selected
based on their laparoscopic tumor load and then randomized on
PDS vs. NACT (ClinicalTrials.gov identiﬁer: NCT01461850, protocol
ID: SCORPION). Here, the reported rate of complete/optimal
cytoreduction at PDS is 91%, which is superimposable with that re-
ported from the German series (Fagotti et al., 2016). The rate of
45.5% of RT= 0 reported in the PDS group seems adequate consider-
ing this setting of patients was selected for having High Tumour Load
(HTL) at S-LPS, as proven by the need of upper abdominal procedures
(UAP) and highly complex surgery in 100% of cases (Fagotti et al.,
2016). Moreover, by this kind of selection (HTL by S-LPS), we were
able to predict the risk of moderate/severe post-operative complica-
tions (52%, including pleural effusion). Survival analysis will clarify
whether aggressive PDS with a high potential rate of severe compli-
cations is an acceptable treatment in AEOC women with HTL.
3. Ourmanagement is in linewith the recent ASCO/SGO practice guide-
lines regarding the use of NACT and interval cytoreduction in stage
IIIC/IV AEOC women (Wright et al., 2016). Based on the series pub-
lished by Vizzielli, the majority of stage III-IV AEOC patients has
low/intermediate tumor load at S-LPS, thus being suitable for imme-
diate PDS with minimal risk for post-operative complications
(Vizzielli et al., 2016). Only about 20%–30% of the entire population
at stage III-IV shows HTL as assessed by S-LPS; they need an accurate
evaluation to balance risks and beneﬁts of aggressive surgery, as
outlined in the SCORPION trial.
4. The last issue, which should be discussed, is the potential role of S-
LPS in affectingpatients' outcome. Some, including the sameAuthors,
have shown a higher risk of port site metastases, a higher surgical
treatment burden and post-operative complication rate in AEOC pa-
tients having S-LPS followed by PDS (Ataseven et al., 2016), thus ad-
vocating a detrimental effect of S-LPS on tumor diffusion. Thesethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
54 Correspondenceconclusions could appear imperative and inconsistent. Excluding po-
tential technical explanations to these ﬁndings (i.e. essufﬂation, irri-
gation, fascial closure, time to PDS), themost reasonable cause seems
to lie in the intrinsic bias of any retrospective study. Indeed, those pa-
tients considered unresectable in other Institutions through S-LPS
did receive debulking in their Hospital with aggressive surgery and
related complications. Results on whether such approach assured
better survival to these patients than planned NACT are still lacking
from RCTs.
The issue whether S-LPS might improve survival seems more in-
triguing. In line with previously published data on a large series of
2655 AEOC patients from GOG182 study (Horowitz et al., 2015), we
ﬁrstly demonstrated that S-LPS could identify women with HTL and
shorter PFS and OS (Vizzielli et al., 2014). We also showed that this var-
iable retained independent prognostic value at multivariate analysis to-
gether with residual tumor. In this context, S-LPS is currently one of the
best tool to stratify patients with AEOC (HTL vs. LTL) and this stratiﬁca-
tion should be incorporated in data analysis from RCT of PDS vs. NACT
(TRUST trial, NCT02828618), to avoid the risk of including unselected
patients. We have much more information, opportunities and expecta-
tions than in the past, which cannot be ignored. The future is designing
small clinical trials for groups of patients, inserted into a clear clinical
scenario, showing speciﬁc markers of the disease. Here, novel therapies
targeted on themolecular defect, or new schedules, doses and combina-
tions could be tested. Only with this stratiﬁcation, we will ﬁnd the best
recipient settings and truly clarify the potential of each strategy. In this
context, S-LPS as well as any other pre-operative approach able to stan-
dardize and categorize clinical pictures, and to allow adequate tissue
acquisition for molecular analysis, is able to indirectly offer an improve-
ment in survival.
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